Spontaneous in vitro IL-6 production in various intestinal segments in patients with inflammatory bowel disease
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Crohn Disease immunology metabolism pathology MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Interleukin-6 biosynthesis immunology MeSH
- Cells, Cultured MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger biosynthesis MeSH
- Polymerase Chain Reaction MeSH
- Intestinal Mucosa immunology metabolism pathology MeSH
- Colitis, Ulcerative immunology metabolism pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- IL6 protein, human MeSH Browser
- Interleukin-6 MeSH
- RNA, Messenger MeSH
Interleukin-6 (IL-6) plays an important role in regulation of intestinal inflammatory processes in inflammatory bowel disease (IBD). The levels of IL-6 in media from cultured biopsy samples were determined by ELISA in 14 Crohn's disease (CD) patients, 17 patients with ulcerative colitis (UC), and 24 healthy controls in terminal ileum, cecum, and rectum. Results were confirmed by measuring mRNA expression in selected patients. In CD patients, there were increased levels of IL-6 (expressed in picograms per milligram of biopsy tissue mass) in terminal ileum compared with controls (median, 617 vs. 90.4; p < 0.001). High IL-6 levels were found in the rectum of CD patients with active disease but normal endoscopic findings (791 vs. 131; p < 0.05). This result was confirmed by mRNA expression. There was a substantial increase of IL-6 levels in cultured cecal (median, 327 vs. 94.0; p < 0.001) and rectal mucosa (median, 282 vs.131; p < 0.05) but not in ileal mucosa of UC patients. In conclusion, IL-6 production was higher in IBD patients than in controls; it correlated with disease activity and varied among different intestinal segments. In clinically active CD patients without rectal involvement, high IL-6 levels in cultured rectal mucosa suggest immune stimulation even in the absence of macroscopic inflammation.
See more in PubMed
J Exp Med. 1994 Oct 1;180(4):1243-50 PubMed
Inflamm Bowel Dis. 2007 Aug;13(8):1016-23 PubMed
Gut. 2002 Nov;51(5):659-64 PubMed
Expert Opin Ther Targets. 2007 May;11(5):613-24 PubMed
Biochim Biophys Acta. 2002 Nov 11;1592(3):323-43 PubMed
Cytokine Growth Factor Rev. 2006 Dec;17(6):451-61 PubMed
Mediators Inflamm. 2009;2009:580450 PubMed
Cochrane Database Syst Rev. 2004;(1):CD003574 PubMed
Digestion. 1991;50(2):104-11 PubMed
J Exp Med. 2008 Sep 1;205(9):2099-110 PubMed
Gastroenterology. 2004 Apr;126(4):989-96; discussion 947 PubMed
Gut. 2000 Mar;46(3):350-8 PubMed
Ann N Y Acad Sci. 2005 Jun;1051:787-98 PubMed
Clin Exp Immunol. 1993 Oct;94(1):174-81 PubMed
Immunol Lett. 2004 May 15;93(2-3):97-108 PubMed
Gut. 1996 Nov;39(5):684-9 PubMed
Gut. 2004 Jan;53(1):1-4 PubMed
J Histochem Cytochem. 2008 Mar;56(3):267-74 PubMed
J Clin Microbiol. 2005 Jul;43(7):3380-9 PubMed
Clin Exp Immunol. 2006 Jan;143(1):125-31 PubMed
Dig Dis Sci. 1995 May;40(5):949-59 PubMed
BMJ. 1989 Jan 14;298(6666):82-6 PubMed
Dig Liver Dis. 2008 Apr;40(4):253-9 PubMed
Nat Med. 2000 May;6(5):583-8 PubMed
